BioCryst Pharmaceuticals, Inc.

BMV:BCRX * Stock Report

Market Cap: Mex$31.8b

BioCryst Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

BioCryst Pharmaceuticals's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 45.7% per year.

Key information

-8.0%

Earnings growth rate

0.3%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate45.7%
Return on equityn/a
Net Margin-30.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BioCryst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:BCRX * Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24413-1242500
30 Jun 24382-1462350
31 Mar 24355-2092250
31 Dec 23331-2272140
30 Sep 23318-2362000
30 Jun 23307-2431860
31 Mar 23290-2261730
31 Dec 22271-2471590
30 Sep 22238-1931520
30 Jun 22204-2101430
31 Mar 22188-1941310
31 Dec 21157-1841190
30 Sep 21114-227970
30 Jun 2179-214870
31 Mar 2132-209740
31 Dec 2018-183630
30 Sep 2054-125520
30 Jun 2049-116470
31 Mar 2048-115420
31 Dec 1949-109370
30 Sep 1912-134310
30 Jun 1912-126270
31 Mar 1923-107330
31 Dec 1821-101300
30 Sep 1822-93300
30 Jun 1829-79250
31 Mar 1820-77140
31 Dec 1725-66140
30 Sep 1730-51120
30 Jun 1729-47110
31 Mar 1731-47110
31 Dec 1626-55110
30 Sep 1622-69110
30 Jun 1625-72110
31 Mar 1646-51120
31 Dec 1548-43130
30 Sep 1549-37120
30 Jun 1541-31110
31 Mar 1517-50100
31 Dec 1414-4570
30 Sep 1419-3970
30 Jun 1418-3870
31 Mar 1417-3660
31 Dec 1317-3060

Quality Earnings: BCRX * is currently unprofitable.

Growing Profit Margin: BCRX * is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BCRX * is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.

Accelerating Growth: Unable to compare BCRX *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: BCRX *'s liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies